Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/17/2025

Management of Hyperglycemia with Hypernatremia

Assessment and Initial Management

  • Point-of-care glucose monitoring should be performed frequently (every 1-2 hours initially) to guide therapy, according to the American Diabetes Association 1

Insulin Therapy

  • For severe hyperglycemia (>250 mg/dL), initiate continuous intravenous insulin infusion at 0.1 units/kg/hour, as recommended by the American College of Endocrinology 2, 3
  • Target a gradual reduction in glucose of 50-75 mg/dL per hour, based on guidelines from the American Diabetes Association 3
  • Once glucose levels reach 200-250 mg/dL, reduce insulin infusion rate and add dextrose-containing fluids to prevent hypoglycemia while continuing to correct hypernatremia, as suggested by the European Association for the Study of Diabetes 2, 4
  • Transition to subcutaneous insulin using a basal-bolus regimen once the patient is stable, with administration of basal insulin 2-4 hours before discontinuing the insulin infusion, according to the American Association of Clinical Endocrinologists 5

Monitoring and Adjustments

  • Monitor serum sodium, potassium, glucose, and osmolality every 2-4 hours initially, as recommended by the American Diabetes Association 1

Special Considerations

  • In critically ill patients, maintain glucose levels between 140-180 mg/dL rather than more intensive control to reduce the risk of hypoglycemia, according to the Society of Critical Care Medicine 6
  • For patients with cardiac or renal disease, careful monitoring of volume status is essential to prevent fluid overload, as suggested by the American Heart Association 7

Transition of Care and Follow-up

  • Develop a structured discharge plan that includes diabetes education, medication reconciliation, and scheduled follow-up, according to the American Diabetes Association 5
  • Consider endocrinology consultation for complex cases or patients with recurrent episodes, as recommended by the Endocrine Society 3

Pitfalls to Avoid

  • Avoid using sliding scale insulin as the sole regimen as it is reactive rather than proactive and associated with poor glycemic control, according to the American Diabetes Association 8
  • Monitor for hypoglycemia, especially during transition from intravenous to subcutaneous insulin, as suggested by the American Association of Clinical Endocrinologists 7